Raytheon awarded $71 million in Navy contracts for missile systems
Investing.com - Morgan Stanley (NYSE:MS) upgraded Halozyme Therapeutics (NASDAQ:HALO), a $7.49 billion biotech company with exceptional financial health, from Equalweight to Overweight on Wednesday, raising its price target to $75.00 from $62.00. According to InvestingPro data, the company maintains a perfect Piotroski Score of 9, indicating strong operational efficiency.
The upgrade follows the passage of the One Big Beautiful Bill, which includes the ORPHAN Cures Act that Morgan Stanley believes provides a positive outlook for Halozyme. The investment firm specifically noted that Vyvgart, Darzalex IV, and the first indication for Opdivo (melanoma) may be excluded from price negotiations. This positive outlook aligns with the company’s strong revenue growth of 25.65% over the last twelve months.
Morgan Stanley had previously maintained a more cautious stance on Halozyme due to regulatory uncertainties stemming from CMS draft guidance. The firm now expresses greater confidence that alleviates some of its prior concerns.
The investment bank also highlighted the opportunity for continued royalty revenue growth for Halozyme, including anticipated indication expansions for Vyvgart, which are not currently included in the company’s long-term guidance.
While acknowledging that other stocks in its coverage may offer greater upside potential, Morgan Stanley values Halozyme’s exposure to a multi-company product portfolio that balances risk, along with what it describes as "ample balance sheet optionality." This assessment is supported by the company’s strong liquidity position, with a current ratio of 8.39. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report, part of InvestingPro’s coverage of over 1,400 US stocks.
In other recent news, Halozyme Therapeutics Inc. reported its Q2 2025 earnings, revealing a mixed financial performance. The company achieved an earnings per share (EPS) of $1.54, which exceeded analysts’ expectations of $1.24, marking a 24.19% increase over projections. Despite this positive earnings result, Halozyme’s revenue fell short of expectations, with actual revenue reported at $206 million compared to the anticipated $286.01 million. This represents a significant revenue miss of 27.97%. These developments highlight the company’s ability to manage earnings efficiently, though it faces challenges in meeting revenue targets. Investors and analysts will likely be assessing these figures closely to understand the broader implications for Halozyme’s financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.